Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical management of BRCA1 and BRCA2 mutation carriers.

Oncogene - 25 Sept 2006

Domchek S M, Weber B L

Abstract excerpt

The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to BRCA1 gene
Share to BRCA2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genetic Carrier Screening

Share to Mutation

Share to Ovarian Neoplasms

Share to Risk Reduction Behavior

Source

Identifiers

PMID: 16998496
DOI: 10.1038/sj.onc.1209881

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical management of BRCA1 and BRCA2 mutation carriers.PMID 16998496Read ↗

The clinical management of BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Management updates for women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.Semantic proximity Read ↗

Clinical management of BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Evaluation and management of women with BRCA1/2 mutations.Semantic proximity Read ↗

Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.Semantic proximity Read ↗

Perspectives in the clinical management of BRCA mutations carriers.Semantic proximity Read ↗

Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.Semantic proximity Read ↗

Identifying and managing hereditary risk of breast and ovarian cancer.Semantic proximity Read ↗

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline VariantsSemantic proximity Read ↗

Clinical Considerations of<i>BRCA1</i>- and<i>BRCA2</i>-Mutation Carriers: A ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.